Logo image of ICPT

INTERCEPT PHARMACEUTICALS IN (ICPT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ICPT - US45845P1084 - Common Stock

19 USD
+0.04 (+0.21%)
Last: 11/7/2023, 8:02:20 PM
19 USD
0 (0%)
After Hours: 11/7/2023, 8:02:20 PM
Fundamental Rating

2

Taking everything into account, ICPT scores 2 out of 10 in our fundamental rating. ICPT was compared to 529 industry peers in the Biotechnology industry. ICPT may be in some trouble as it scores bad on both profitability and health. ICPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ICPT has reported negative net income.
ICPT had a negative operating cash flow in the past year.
In the past 5 years ICPT reported 4 times negative net income.
ICPT had a negative operating cash flow in each of the past 5 years.
ICPT Yearly Net Income VS EBIT VS OCF VS FCFICPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

1.2 Ratios

ICPT's Return On Assets of -15.67% is amongst the best of the industry. ICPT outperforms 84.91% of its industry peers.
ICPT has a Return On Equity (-85.76%) which is in line with its industry peers.
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROIC N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICPT Yearly ROA, ROE, ROICICPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

1.3 Margins

ICPT's Gross Margin of 99.80% is amongst the best of the industry. ICPT outperforms 99.17% of its industry peers.
ICPT's Gross Margin has been stable in the last couple of years.
ICPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
ICPT Yearly Profit, Operating, Gross MarginsICPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICPT has more shares outstanding than it did 1 year ago.
ICPT has a better debt/assets ratio than last year.
ICPT Yearly Shares OutstandingICPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ICPT Yearly Total Debt VS Total AssetsICPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -5.03, we must say that ICPT is in the distress zone and has some risk of bankruptcy.
ICPT has a worse Altman-Z score (-5.03) than 66.17% of its industry peers.
ICPT has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.12, ICPT is doing worse than 85.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Altman-Z -5.03
ROIC/WACCN/A
WACC10.19%
ICPT Yearly LT Debt VS Equity VS FCFICPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

ICPT has a Current Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
ICPT has a Current ratio (4.22) which is comparable to the rest of the industry.
ICPT has a Quick Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.22, ICPT perfoms like the industry average, outperforming 43.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.22
ICPT Yearly Current Assets VS Current LiabilitesICPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ICPT have decreased strongly by -125.05% in the last year.
ICPT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.64%.
The Revenue has been growing by 16.88% on average over the past years. This is quite good.
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%

3.2 Future

ICPT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.89% yearly.
ICPT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.71% yearly.
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICPT Yearly Revenue VS EstimatesICPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ICPT Yearly EPS VS EstimatesICPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ICPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 9.11, which indicates a very decent valuation of ICPT.
Based on the Price/Forward Earnings ratio, ICPT is valued cheaper than 99.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ICPT to the average of the S&P500 Index (23.68), we can say ICPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.11
ICPT Price Earnings VS Forward Price EarningsICPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICPT Per share dataICPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as ICPT's earnings are expected to decrease with -33.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%

More info and screens

0

5. Dividend

5.1 Amount

ICPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERCEPT PHARMACEUTICALS IN

NASDAQ:ICPT (11/7/2023, 8:02:20 PM)

After market: 19 0 (0%)

19

+0.04 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2023-11-06/amc
Earnings (Next)02-29 2024-02-29/amc
Inst Owners0.17%
Inst Owner Change0%
Ins Owners10.38%
Ins Owner Change0%
Market Cap794.39M
Revenue(TTM)317.68M
Net Income(TTM)-61.61M
Analysts70
Price Target19.38 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.4%
Min EPS beat(2)73.02%
Max EPS beat(2)117.78%
EPS beat(4)2
Avg EPS beat(4)-7.36%
Min EPS beat(4)-203.66%
Max EPS beat(4)117.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-1.65%
Max Revenue beat(2)3.15%
Revenue beat(4)1
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-7.75%
Max Revenue beat(4)3.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.63%
PT rev (3m)24.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)660.22%
EPS NY rev (1m)0%
EPS NY rev (3m)3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.11
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 11.06
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)2.09
Fwd EY10.98%
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS7.6
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.34%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.22
Altman-Z -5.03
F-Score3
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)78.24%
Cap/Depr(5y)53.92%
Cap/Sales(3y)0.53%
Cap/Sales(5y)0.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%
EBIT growth 1Y30.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.22%
EBIT Next 3Y46.24%
EBIT Next 5YN/A
FCF growth 1Y2.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.28%
OCF growth 3YN/A
OCF growth 5YN/A

INTERCEPT PHARMACEUTICALS IN / ICPT FAQ

What is the ChartMill fundamental rating of INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ICPT.


What is the valuation status for ICPT stock?

ChartMill assigns a valuation rating of 2 / 10 to INTERCEPT PHARMACEUTICALS IN (ICPT). This can be considered as Overvalued.


How profitable is INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

INTERCEPT PHARMACEUTICALS IN (ICPT) has a profitability rating of 2 / 10.


What is the earnings growth outlook for INTERCEPT PHARMACEUTICALS IN?

The Earnings per Share (EPS) of INTERCEPT PHARMACEUTICALS IN (ICPT) is expected to decline by -122.07% in the next year.